Abbott’s Branded Drug Spin-off Will Boost Profile Of Diversified Device Biz

Abbott’s planned spin-off of its branded pharmaceuticals business will raise the profile of its remaining diversified device and diagnostics business while isolating certain long-term risks, including generic drug competition.